MedTrace Logo

Dolutegravir Expanded Access Study

NCT01536873 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-09-30

No results posted yet for this study

Summary

ING114916 is an open-label, multi-center, expanded access (EAP) study

Conditions

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Interventions

DRUG

Dolutegravir

Eligible patients will receive DTG 50 mg given orally BID

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-14
Primary Completion
2016-09-23
Completion
2016-09-23

Countries

  • United States
  • Austria
  • Belgium
  • Brazil
  • Canada
  • France
  • Germany
  • Italy
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536873 on ClinicalTrials.gov